Dietary lipids and adipocytes: Potential therapeutic targets in cancers

Journal of Nutritional Biochemistry

Volumn 26, Issue 4, 2015, Pages 303-311

  Kwan, Hiu Yee ^a   Chao, Xiaojuan ^a   Su, Tao ^a   Fu, Xiu Qiong ^a   Liu, Bin ^b   Tse, Anfernee Kai Wing ^a   Fong, Wang Fun ^a   Yu, Zhi Ling ^a  

^a HONG KONG BAPTIST UNIVERSITY   (Hong Kong)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Adipocytes; Cancer; Lipids; Microenvironment; Obesity

Indexed keywords

ACETYL COENZYME A; ADENOSINE TRIPHOSPHATE CITRATE SYNTHASE; ARACHIDONIC ACID; CITRIC ACID; DOCOSAHEXAENOIC ACID; FATTY ACID; ICOSAPENTAENOIC ACID; LINOLENIC ACID; LIPID; MALONYL COENZYME A; OLEIC ACID; OMEGA 3 FATTY ACID; PALMITIC ACID; PHYTANIC ACID; STEARIC ACID; FAT INTAKE;

ADIPOCYTE; ADIPOSE TISSUE; BREAST CANCER; CACHEXIA; CANCER CELL; CANCER GROWTH; CARCINOGENESIS; CELL INTERACTION; CELL PROLIFERATION; COLON CANCER; FAT INTAKE; FATTY ACID SYNTHESIS; HUMAN; LIPID METABOLISM; LIPID STORAGE; LIPID TRANSPORT; LIPOLYSIS; MELANOMA; METASTASIS; NEOPLASM; NONHUMAN; OBESITY; OVARY CANCER; PATHOGENESIS; PROSTATE CANCER; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ADIPOGENESIS; ANIMAL; BIOSYNTHESIS; CELL TRANSFORMATION; METABOLISM; TUMOR CELL LINE;

ADIPOCYTES; ADIPOGENESIS; ADIPOSE TISSUE; ANIMALS; CACHEXIA; CARCINOGENESIS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DIETARY FATS; FATTY ACIDS; HUMANS; NEOPLASMS; TUMOR MICROENVIRONMENT;

EID: 84925297701     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2014.11.001     Document Type: Review

References (147)

1. Santos C.R., Schulze A. Lipid metabolism in cancer. FEBS J 2012, 279:2610-2623.
2. Teo K., Brunton V.G. The role and therapeutic potential of the autotaxin-lysophosphatidate signalling axis in breast cancer. Biochem J 2014, 463:157-165.
3. Mills G.B., Moolenaar W.H. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003, 3:582-591.
4. Gupta G.P., Nguyen D.X., Chiang A.C., Bos P.D., Kim J.Y., Nadal C., et al. Mediators of vascular remodelling co-opted for sequential steps in lung metastasis. Nature 2007, 446:765-770.
5. Misra S., Sharma K. COX-2 signaling and cancer: new players in old arena. Curr Drug Targets 2014, 15:347-359.
6. Resh M.D. Palmitoylation of ligands, receptors, and intracellular signaling molecules. Sci STKE 2006, 2006:re14.
7. Linder M.E., Deschenes R.J. Palmitoylation: policing protein stability and traffic. Nat Rev Mol Cell Biol 2007, 8:74-84.
8. Takada R., Satomi Y., Kurata T., Ueno N., Norioka S., Kondoh H., et al. Monounsaturated fatty acid modification of Wnt protein: its role in Wnt secretion. Dev Cell 2006, 11:791-801.
9. Babina I.S., McSherry E.A., Donatello S., Hill A.D., Hopkins A.M. A novel mechanism of regulating breast cancer cell migration via palmitoylation-dependent alterations in the lipid raft affiliation of CD44. Breast Cancer Res 2014, 16:R19.
10. Fiorentino M., Zadra G., Palescandolo E., Fedele G., Bailey D., Foire C., et al. Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of beta-catenin in prostate cancer. Lab Invest 2008, 88:1340-1348.
11. Furuta E., Okuda H., Kobayashi A., Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta 1805, 2010:141-152.
12. Schulze A., Harris A.L. How cancer metabolism is tuned for proliferation and vulnerable to disruption. Nature 2012, 491:364-373.
13. Moreno-Sánchez R., Rodríguez-Enríquez S., Marín-Hernández A., Saavedra E. Energy metabolism in tumor cells. FEBS J 2007, 274:1393-1418.
14. Ralph S.J., Low P., Dong L., Lawen A., Neuzil J. 2006 Mitocans: mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents. Recent Pat Anticancer Drug Discov 2006, 1(3):327-346.
15. Currie E., Schulze A., Zechner R., Walther T.C., Farese R.V. Cellular fatty acid metabolism and cancer. Cell Metab 2013, 18:153-161.
16. Catalina-Rodriguez O., Kolukula V.K., Tomita Y., Preet A., Palmieri F., Wellstein A., et al. The mitochondrial citrate transporter, CIC, is essential for mitochondrial homeostasis. Oncotarget 2012, 3:1220-1235.
17. Hopperton K.E., Duncan R.E., Bazinet R.P., Archer M.C. Fatty acid synthase plays a role in cancer metabolism beyond providing fatty acids for phospholipid synthesis or sustaining elevations in glycolytic activity. Exp Cell Res 2014, 320:302-310.
18. Khandekar M.J., Cohen P., Spiegelman B.M. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer 2011, 11:886-895.
19. Zaidi N., Lupien L., Kuemmerle N.B., Kinlaw W.B., Swinnen J.V., Smans K. Lipogenesis and lipolysis: the pathways exploited by the cancer cells to acquire fatty acids. Prog Lipid Res 2013, 52:585-589.
20. Swinnen J.V., Brusselmans K., Verhoeven G. Increased lipogenesis in cancer cells: new players, novel targets. Curr Opin Clin Nutr Metab Care 2006, 9:358-365.
21. Kuhajda F.P. Fatty acid synthase and cancer: new application of an old pathway. Cancer Res 2006, 66:5977-5980.
22. Mashima T., Seimiya H., Tsuruo T. De novo fatty-acid synthesis and related pathways as molecular targets for cancer therapy. Br J Cancer 2009, 100:1369-1372.
23. Ameer F., Scandiuzzi L., Hasnain S., Kalbacher H., Zaidi N. De novo lipogenesis in health and disease. Metabolism 2014, 63:895-902.
24. Wang C., Rajput S., Watabe K., Liao D.F., Cao D. Acetyl-CoA carboxylase-a as a novel target for cancer therapy. Front Biosci 2010, 2:515-526.
25. Brusselmans K., De Schrijver E., Verhoeven G., Swinnen J.V. RNA interference-mediated silencing of the acetyl-CoA-carboxylase-alpha gene induces growth inhibition and apoptosis of prostate cancer cells. Cancer Res 2005, 65:6719-6725.
26. Pizer E.S., Thupari J., Han W.F., Pinn M.L., Chrest F.J., Frehywot G.L., et al. Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 2000, 60:213-218.
27. Conde E., Suarez-Gauthier A., García-García E., Lopez-Rios F., Lopez-Encuentra A., Gracia-Lujan R., et al. Specific pattern of LKB1 and phospho-acetyl-CoA carboxylase protein immunostaining in human normal tissues and lung carcinomas. Hum Pathol 2007, 38:1351-1360.
28. Zhou W., Tu Y., Simpson P.J., Kuhajda F.P. Malonyl-CoA decarboxylase inhibition is selectively cytotoxic to human breast cancer cells. Oncogene 2009, 28:2979-2987.
29. Madigan A.A., Rycyna K.J., Parwani A.V., Datiri Y.J., Basudan A.M., Sobek K.M., et al. Novel nuclear localization of fatty acid synthase correlates with prostate cancer aggressiveness. Am J Pathol 2014, 184:2156-2162.
30. Sugino T., Baba K., Hoshi N., Aikawa K., Yamaguchi O., Suzuki T. Overexpression of fatty acid synthase in human urinary bladder cancer and combined expression of the synthase and Ki-67 as a predictor of prognosis of cancer patients. Med Mol Morphol 2011, 44:146-150.
31. Bandyopadhyay S., Pai S.K., Watabe M., Gross S.C., Hirota S., Hosobe S. FAS expression inversely correlates with PTEN level in prostate cancer and a PI 3-kinase inhibitor synergizes with FAS siRNA to induce apoptosis. Oncogene 2005, 24:5389-5395.
32. Esslimani-Sahla M., Thezenas S., Simony-Lafontaine J., Kramar A., Lavaill R., Chalbos D., et al. Increased expression of fatty acid synthase and progesterone receptor in early steps of human mammary carcinogenesis. Int J Cancer 2007, 120:224-229.
33. Qiu C., Dongol S., Lv Q.T., Gao X., Jiang J. Sterol regulatory element-binding protein-1/fatty acid synthase involvement in proliferation inhibition and apoptosis promotion induced by progesterone in endometrial cancer. Int J Gynecol Cancer 2013, 23:1629-1634.
34. Lupu R., Menendez J.A. Targeting fatty acid synthase in breast and endometrial cancer: an alternative to selective estrogen receptor modulators?. Endocrinology 2006, 147:4056-4066.
35. Rochefort H., Chalbos D. The role of sex steroid receptors on lipogenesis in breast and prostate carcinogenesis: a viewpoint. Horm Cancer 2010, 1:63-70.
36. Menendez J.A., Vellon L., Mehmi I., Oza B.P., Ropero S., Colomer R., et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci U S A 2004, 101:10715-10720.
37. Santolla M.F., Lappano R., De Marco P., Pupo M., Vivacqua A., Sisci D., et al. G protein-coupled estrogen receptor mediates the up-regulation of fatty acid synthase induced by 17β-estradiol in cancer cells and cancer-associated fibroblasts. J Biol Chem 2012, 287:43234-43245.
38. Heemers H., Maes B., Foufelle F., Heyns W., Verhoeven G., Swinnen J.V. Androgens stimulate lipogenic gene expression in prostate cancer cells by activation of the sterol regulatory element-binding protein cleavage activating protein/sterol regulatory element-binding protein pathway. Mol Endocrinol 2001, 15:1817-1828.
39. Furuta E., Pai S.K., Zhan R., Bandyopadhyay S., Watabe M., Mo Y.Y., et al. Fatty acid synthase gene is up-regulated by hypoxia via activation of Akt and sterol regulatory element binding protein-1. Cancer Res 2008, 68:1003-1011.
40. Menendez J.A., Decker J.P., Lupu R. In support of fatty acid synthase (FAS) as a metabolic oncogene: extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J Cell Biochem 2005, 94:1-4.
41. Kwan H.Y., Yang Z., Fong W.F., Hu Y.M., Yu Z.L., Hsiao W.L. The anticancer effect of oridonin is mediated by fatty acid synthase suppression in human colorectal cancer cells. J Gastroenterol 2013, 48:182-192.
42. Chajès V., Cambot M., Moreau K., Lenoir G.M., Joulin V. Acetyl-CoA carboxylase alpha is essential to breast cancer cell survival. Cancer Res 2006, 66:5287-5294.
43. Tamura K., Makino A., Hullin-Matsuda F., Kobayashi T., Furihata M., Chung S., et al. Novel lipogenic enzyme ELOVL7 is involved in prostate cancer growth through saturated long-chain fatty acid metabolism. Cancer Res 2009, 69:8133-8140.
44. Cao Y., Pearman A.T., Zimmerman G.A., McIntyre T.M., Prescott S.M. Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci U S A 2000, 97:11280-11285.
45. Mashima T., Oh-hara T., Sato S., Mochizuki M., Suqimoto Y., Yamazaki K., et al. p53-defective tumors with a functional apoptosome-mediated pathway: a new therapeutic target. J Natl Cancer Inst 2005, 97:765-777.
46. Igal R.A. Stearoyl-CoA desaturase-1: a novel key player in the mechanisms of cell proliferation, programmed cell death and transformation to cancer. Carcinogenesis 2010, 31:1509-1515.
47. Ariyama H., Kono N., Matsuda S., Inoue T., Arai H. Decrease in membrane phospholipid unsaturation induces unfolded protein response. J Biol Chem 2010, 285:22027-22035.
48. Bauer D.E., Hatzivassiliou G., Zhao F., Andreadis C., Thompson C.B. ATP citrate lyase is an important component of cell growth and transformation. Oncogene 2005, 24:6314-6322.
49. Hatzivassiliou G., Zhao F., Bauer D.E., Andreadis C., Shaw A.N., Dhanak D., et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cancer Cell 2005, 8:311-321.
50. Migita T., Narita T., Nomura K., Miyaqi E., Inazuka F., Matsuura M., et al. ATP citrate lyase: activation and therapeutic implications in non-small cell lung cancer. Cancer Res 2008, 68:8547-8554.
51. Li J.N., Mahmoud M.A., Han W.F., Ripple M., Pizer E.S. Sterol regulatory element-binding protein-1 participates in the regulation of fatty acid synthase expression in colorectal neoplasia. Exp Cell Res 2000, 261:159-165.
52. Ettinger S.L., Sobel R., Whitmore T.G., Akbari M., Bradley D.R., Gleave M.E., et al. Dysregulation of sterol response element-binding proteins and downstream effectors in prostate cancer during progression to androgen independence. Cancer Res 2004, 64:2212-2221.
53. Huang W.C., Li X., Liu J., Lin J., Chung L.W. Activation of androgen receptor, lipogenesis, and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res 2012, 10:133-142.
54. Hilvo M., Denkert C., Lehtinen L., Muller B., Brockmoller S., Seppanen-Laakso T., et al. Novel theranostic opportunities offered by characterization of altered membrane lipid metabolism in breast cancer progression. Cancer Res 2011, 71:3236-3245.
55. Guo D., Bell E.H., Mischel P., Chakravarti A. Targeting SREPB1-driven lipid metabolism to treat cancer. Curr Pharm Des 2014, 20(15):2619-2626.
56. Duncan R.E., Ahmadian M., Jaworski K., Sarkadi-Nagy E., Sul H.S. Regulation of lipolysis in adipocytes. Annu Rev Nutr 2007, 27:79-101.
57. Nomura D.K., Long J.Z., Niessen S., Hoover H.S., Ng S.W., Cravatt B.F. Monoacylglycerol lipase regulates a fatty acid network that promotes cancer pathogenesis. Cell 2010, 140:49-61.
58. Spector A.A. The importance of free fatty acid in tumor nutrition. Cancer Res 1967, 27:1580-1586.
59. Tisdale M.J. Mechanisms of cancer cachexia. Physiol Rev 2009, 89:381-410.
60. Tan C.R., Yaffee P.M., Jamil L.H., Lo S.K., Nissen N., Pandol S.J., et al. Pancreatic cancer cachexia: a review of mechanisms and therapeutics. Front Physiol 2014, 5:88.
61. Bing C., Trayhurn P. Regulation of adipose tissue metabolism in cancer cachexia. Curr Opin Clin Nutr Metab Care 2008, 11:201-207.
62. Fleshner N., Bagnell P.S., Klotz L., Venkateswaran V. Dietary fat and prostate cancer. J Urol 2004, 171:S19-S24.
63. VanSaun M.N., Lee I.K., Washington M.K., Matrisian L., Gorden D.L. High fat diet induced hepatic steatosis establishes a permissive microenvironment for colorectal metastases and promotes primary dysplasia in a murine model. Am J Pathol 2009, 175:355-364.
64. Hsiao W.L., Pai H.L., Matsui M.S., Weinstein I.B. Effects of specific fatty acids on cell transformation induced by an activated c-H-ras oncogene. Oncogene 1990, 5:417-421.
65. Nkondjock A., Shatenstein B., Maisonneuve P., Ghadirian P. Assessment of risk associated with specific fatty acids and colorectal cancer among French-Canadians in Montreal: a case-control study. Int J Epidemiol 2003, 32:200-209.
66. Jackson M.D., Walker S.P., Simpson-Smith C.M., Lindsay C.M., Smith G., McFarlane-Anderson N., et al. Associations of whole-blood fatty acids and dietary intakes with prostate cancer in Jamaica. Cancer Causes Control 2012, 23:23-33.
67. Moreel X., Allaire J., Léger C., Caron A., Labonté M.È., Lamarche B., et al. Prostatic and dietary omega-3 fatty acids and prostate cancer progression during active surveillance. Cancer Prev Res (Phila) 2014, 7:766-776.
68. Dennis L.K., Snetselaar L.G., Smith B.J., Stewart R.E., Robbins M.E. Problems with the assessment of dietary fat in prostate cancer studies. Am J Epidemiol 2004, 160:436-444.
69. Eser P.O., Vanden Heuvel J.P., Araujo J., Thompson J.T. Marine- and plant-derived ω-3 fatty acids differentially regulate prostate cancer cell proliferation. Mol Clin Oncol 2013, 1:444-452.
70. Ralph S.J., Rodríguez-Enríquez S., Neuzil J., Moreno-Sánchez R. Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger. Mol Aspects Med 2010, 31:29-59.
71. Wongtangtintharn S., Oku H., Iwasaki H., Inafuku M., Toda T., Yanagita T. Incorporation of branched-chain fatty acid into cellular lipids and caspase-independent apoptosis in human breast cancer cell line, SKBR-3. Lipids Health Dis 2005, 4:29.
72. Al-Wahab Z., Tebbe C., Chhina J., Dar S.A., Morris R.T., Ali-Fehmi R., et al. Dietary energy balance modulates ovarian cancer progression and metastasis. Oncotarget 2014, 5:6063-6075.
73. Zhang Y., Daquinag A.C., Amaya-Manzanares F., Sirin O., Tseng C., Kolonin M.G. Stromal progenitor cells from endogenous adipose tissue contribute to pericytes and adipocytes that populate the tumor microenvironment. Cancer Res 2012, 72:5198-5208.
74. Gazi E., Gardner P., Lockyer N.P., Hart C.A., Brown M.D., Clarke N.W. Direct evidence of lipid translocation between adipocytes and prostate cancer cells with imaging FTIR microspectroscopy. J Lipid Res 2007, 48:1846-1856.
75. Nieman K.M., Kenny H.A., Penicka C.V., Ladanyi A., Buell-Gutbrod R., Zillhardt M.R., et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 2011, 17:1498-1503.
76. Martinez-Outschoorn U.E., Sotgia F., Lisanti M.P. Power surge: supporting cells "fuel" cancer cell mitochondria. Cell Metab 2012, 15:4-5.
77. Proebstle T.M., Huber R., Sterry W. Detection of early micrometastases in subcutaneous fat of primary malignant melanoma patients by identification of tyrosinase-mRNA. Eur J Cancer 1996, 32A:1664-1667.
78. Mistry T., Digby J.E., Desai K.M., Randeva H.S. Obesity and prostate cancer: a role for adipokines. Eur Urol 2007, 52:46-53.
79. Nieman K.M., Romero I.L., Van Houten B., Lengyel E. Adipose tissue and adipocytes support tumorigenesis and metastasis. Biochim Biophys Acta 1831, 2013:1533-1541.
80. Adib T.R., Henderson S., Perrett C., Hewitt D., Bourmpoulia D., Ledermann J., et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 2004, 90:686-692.
81. Dirat B., Bochet L., Dabek M., Daviaud D., Dauvillier S., Majed B., et al. Cancer-associated adipocytes exhibit an activated phenotype and contribute to breast cancer invasion. Cancer Res 2011, 71:2455-2465.
82. Toren P., Mora B.C., Venkateswaran V. Diet, obesity, and cancer progression: are adipocytes the link?. Lipid Insights 2013, 6:37-45.
83. Brown K.A., Simpson E.R. Obesity and breast cancer: progress to understanding the relationship. Cancer Res 2010, 70:4-7.
84. Kershaw E.E., Flier J.S. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004, 89:2548-2556.
85. Newman G., Gonzalez-Perez R.R. Leptin-cytokine crosstalk in breast cancer. Mol Cell Endocrinol 2014, 382:570-582.
86. Cirillo D., Rachiglio A.M., la Montagna R., Giordano A., Normanno N. Leptin signaling in breast cancer: an overview. J Cell Biochem 2008, 105:956-964.
87. López Fontana C.M., Maselli M.E., Pérez Elizalde R.F., Di Milta Mónaco N.A., Uvilla Recupero A.L., López Laur J.D. Leptin increases prostate cancer aggressiveness. J Physiol Biochem 2011, 67:531-538.
88. Tamakoshi K., Toyoshima H., Wakai K., Kojima M., Suzuki K., Watanabe Y., et al. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncology 2005, 68:454-461.
89. Dubois V., Jardé T., Delort L., Billard H., Bernard-Gallon D., Berger E., et al. Leptin induces a proliferative response in breast cancer cells but not in normal breast cells. Nutr Cancer 2014, 66:645-655.
90. Hoda M.R., Theil G., Mohammed N., Fischer K., Fornara P. The adipocyte-derived hormone leptin has proliferative actions on androgen-resistant prostate cancer cells linking obesity to advanced stages of prostate cancer. J Oncol 2012, 2012:280386.
91. Choi J.H., Park S.H., Leung P.C., Choi K.C. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab 2005, 90:207-210.
92. Catalano S., Mauro L., Marsico S., Giordano C., Rizza P., Rago V., et al. Leptin induces, via ERK1/ERK2 signal, functional activation of estrogen receptor alpha in MCF-7 cells. J Biol Chem 2004, 279:19908-19915.
93. Somasundar P., Yu A.K., Vona-Davis L., McFadden D.W. Differential effects of leptin on cancer in vitro. J Surg Res 2003, 113:50-55.
94. Amemori S., Ootani A., Aoki S., Fujise T., Shimoda R., Kakimoto T., et al. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am J Physiol Gastrointest Liver Physiol 2007, 292:G923-G929.
95. Lee S.A., Sung H., Han W., Noh D.Y., Ahn S.H., Kang D. Serum adiponectin but not leptin at diagnosis as a predictor of breast cancer survival. Asian Pac J Cancer Prev 2014, 15:6137-6143.
96. Osório C.F., Souza D.B., Gallo C.B., Costa W.S., Sampaio F.J. Leptin and leptin receptor expressions in prostate tumors may predict disease aggressiveness?. Acta Cir Bras 2014, 29(Suppl. 3):44-48.
97. Tian Y.F., Chu C.H., Wu M.H., Chang C.L., Yang T., Chou Y.C., et al. Anthropometric measures, plasma adiponectin, and breast cancer risk. Endocr Relat Cancer 2007, 14:669-677.
98. Sher D.J., Oh W.K., Jacobus S., Regan M.M., Lee G.S., Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate 2008, 68:1592-1598.
99. Nagaraju G.P., Aliya S., Alese O.B. Role of adiponectin in obesity related gastrointestinal carcinogenesis. Cytokine Growth Factor Rev 2014, [pii: S1359-6101(14)00061-6]. 10.1016/j.cytogfr.2014.06.007.
100. Cust A.E., Kaaks R., Friedenreich C., Bonnet F., Laville M., Lukanova A., et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab 2007, 92:255-263.
101. Kim A.Y., Lee Y.S., Kim K.H., Lee J.H., Lee H.K., Jang S.H., et al. Adiponectin represses colon cancer cell proliferation via AdipoR1- and -R2-mediated AMPK activation. Mol Endocrinol 2010, 24:1441-1452.
102. Sharma D., Wang J., Fu P.P., Sharma S., Nagalingam A., Mells J., et al. Adiponectin antagonizes the oncogenic actions of leptin in hepatocellular carcinogenesis. Hepatology 2010, 52:1713-1722.
103. Harvey A.E., Lashinger L.M., Hursting S.D. The growing challenge of obesity and cancer: an inflammatory issue. Ann N Y Acad Sci 2011, 1229:45-52.
104. Hebbard L., Ranscht B. Multifaceted roles of adiponectin in cancer. Best Pract Res Clin Endocrinol Metab 2014, 28:59-69.
105. Kelesidis I., Kelesidis T., Mantzoros C.S. Adiponectin and cancer: a systematic review. Br J Cancer 2006, 94:1221-1225.
106. Barb D., Williams C.J., Neuwirth A.K., Mantzoros C.S. Adiponectin in relation to malignancies: a review of existing basic research and clinical evidence. Am J Clin Nutr 2007, 86:s858-s866.
107. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357:539-545.
108. Roberts D.L., Dive C., Renehan A.G. Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med 2010, 61:301-316.
109. Guerrero J., Tobar N., Cáceres M., Espinoza L., Escobar P., Dotor J., et al. Soluble factors derived from tumor mammary cell lines induce a stromal mammary adipose reversion in human and mice adipose cells. Possible role of TGF-beta1 and TNF-alpha. Breast Cancer Res Treat 2010, 119:497-508.
110. Inouye K.E., Shi H., Howard J.K., Daly C.H., Lord G.M., Rollins B.J., et al. Absence of CC chemokine ligand 2 does not limit obesity-associated infiltration of macrophages into adipose tissue. Diabetes 2007, 56:2242-2250.
111. Park J., Morley T.S., Kim M., Clegg D.J., Scherer P.E. Obesity and cancer-mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol 2014, 10:455-465.
112. Charrière G., Cousin B., Arnaud E., André M., Bacou F., Penicaud L., et al. Preadipocyte conversion to macrophage. Evidence of plasticity. J Biol Chem 2003, 278:9850-9855.
113. Khan S., Shukla S., Sinha S., Meeran S.M. Role of adipokines and cytokines in obesity-associated breast cancer: therapeutic targets. Cytokine Growth Factor Rev 2013, 24:503-513.
114. Ribeiro R., Monteiro C., Cunha V., Oliveira M.J., Freitas M., Fraga A., et al. Human periprostatic adipose tissue promotes prostate cancer aggressiveness in vitro. J Exp Clin Cancer Res 2012, 31:32.
115. Finley D.S., Calvert V.S., Inokuchi J., Lau A., Narula N., Petricoin E.F., et al. Periprostatic adipose tissue as a modulator of prostate cancer aggressiveness. J Urol 2009, 182:1621-1627.
116. Catalán V., Gómez-Ambrosi J., Rodríguez A., Frühbeck G. Adipose tissue immunity and cancer. Front Physiol 2013, 4:275.
117. Lashinger L.M., Ford N.A., Hursting S.D. Interacting inflammatory and growth factor signals underlie the obesity-cancer link. J Nutr 2014, 144:109-113.
118. Currie C.J., Poole C.D., Gale E.A. The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009, 52:1766-1777.
119. Jonasson J.M., Ljung R., Talbäck M., Haglund B., Gudbjörnsdòttir S., Steineck G. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009, 52:1745-1754.
120. Govindarajan R., Ratnasinghe L., Simmons D.L., Siegel E.R., Midathada M.V., Kim L., et al. Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes. J Clin Oncol 2007, 25:1476-1481.
121. Shaw R.J., Lamia K.A., Vasquez D., Koo S.H., Bardeesy N., Depinho R.A., et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 2005, 310:1642-1646.
122. Kalender A., Selvaraj A., Kim S.Y., Gulati P., Brule S., Biollet B., et al. Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 2010, 11:390-401.
123. Buzzai M., Bauer D.E., Jones R.G., Deberardinis R.J., Hatzivassillou G., Elstrom R.L., et al. The glucose dependence of Akt-transformed cells can be reversed by pharmacologic activation of fatty acid beta-oxidation. Oncogene 2005, 24:4165-4173.
124. Elstrom R.L., Bauer D.E., Buzzai M., Barnauskas R., Harris M.H., Plas D.R., et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res 2004, 64:3892-3899.
125. Manning B.D., Cantley L.C. AKT/PKB signaling: navigating downstream. Cell 2007, 129:1261-1274.
126. Manabe Y., Toda S., Miyazaki K., Sugihara H. Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions. J Pathol 2003, 201:221-228.
127. Pavlides S., Whitaker-Menezes D., Castello-Cros R., Flomenberg N., Witkiewicz A.K., Frank P.G., et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009, 8:3984-4001.
128. Menendez J.A., Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007, 7:763-777.
129. Tian W.X., Li L.C., Wu X.D., Chen C.C. Weight reduction by Chinese medicinal herbs may be related to inhibition of fatty acid synthase. Life Sci 2004, 74:2389-2399.
130. Chen C., Han X., Zou X., Li Y., Yang L., Cao K., et al. 4-Methylene-2-octyl-5-oxotetrahydrofuran-3-carboxylic acid (C75), an inhibitor of fatty-acid synthase, suppresses the mitochondrial fatty acid synthesis pathway and impairs mitochondrial function. J Biol Chem 2014, 289:17184-17194.
131. Samudio I., Harmancey R., Fiegl M., Kantarjian H., Konopleva M., Korchin B., et al. Pharmacologic inhibition of fatty acid oxidation sensitizes human leukemia cells to apoptosis induction. J Clin Invest 2010, 120:142-156.
132. Pike L.S., Smift A.L., Croteau N.J., Ferrick D.A., Wu M. Inhibition of fatty acid oxidation by etomoxir impairs NADPH production and increases reactive oxygen species resulting in ATP depletion and cell death in human glioblastoma cells. Biochim Biophys Acta 1807, 2011:726-734.
133. Hernlund E., Ihrlund L.S., Khan O., Ates Y.O., Linder S., Panaretakis T., et al. Potentiation of chemotherapeutic drugs by energy metabolism inhibitors 2-deoxyglucose and etomoxir. Int J Cancer 2008, 123:476-483.
134. Iversen P.O., Sørensen D.R., Tronstad K.J., Gudbrandsen O.A., Rustan A.C., Berge R.K., et al. A bioactively modified fatty acid improves survival and impairs metastasis in preclinical models of acute leukemia. Clin Cancer Res 2006, 12:3525-3531.
135. Berge K., Tronstad K.J., Bohov P., Madsen L., Berge R.K. Impact of mitochondrial beta-oxidation in fatty acid-mediated inhibition of glioma cell proliferation. J Lipid Res 2003, 44:118-127.
136. Nomura D.K., Lombardi D.P., Chang J.W., Niessen S., Ward A.M., Long J.Z., et al. Monoacylglycerol lipase exerts dual control over endocannabinoid and fatty acid pathways to support prostate cancer. Chem Biol 2011, 18:846-856.
137. Uehara H., Takahashi T., Oha M., Ogawa H., Izumi K. Exogenous fatty acid binding protein 4 promotes human prostate cancer cell progression. Int J Cancer 2014, 135:2558-2568.
138. D'Esposito V., Passaretti F., Hammarstedt A., Liquoro D., Terraccinao D., Molea G., et al. Adipocyte-released insulin-like growth factor-1 is regulated by glucose and fatty acids and controls breast cancer cell growth in vitro. Diabetologia 2012, 55:2811-2822.
139. Chi M., Chen J., Ye Y., Tseng H.Y., Lai F., Tay K.H., et al. Adipocytes contribute to resistance of human melanoma cells to chemotherapy and targeted therapy. Curr Med Chem 2014, 21:1255-1267.
140. Ellerhorst J.A., Diwan A.H., Dang S.M., Uffort D.G., Johnson M.K., Cooke C.P., et al. Promotion of melanoma growth by the metabolic hormone leptin. Oncol Rep 2010, 23:901-907.
141. Kushiro K., Chu R.A., Verma A., Núñez N.P. Adipocytes promote B16BL6 melanoma cell invasion and the epithelial-to-mesenchymal transition. Cancer Microenviron 2012, 5:73-82.
142. Kushiro K., Núñez N.P. Ob/ob serum promotes a mesenchymal cell phenotype in B16BL6 melanoma cells. Clin Exp Metastasis 2011, 28:877-886.
143. Brandon E.L., Gu J.W., Cantwell L., He Z., Wallace G., Hall J.E. besity promotes melanoma tumor growth: role of leptin. Cancer Biol Ther 2009, 8:1871-1879.
144. Inoue T., Toda S., Narisawa Y., Sugihara H. Subcutaneous adipocytes promote the differentiation of squamous cell carcinoma cell line (DJM-1) in collagen gel matrix culture. J Invest Dermatol 2001, 117:244-250.
145. Sierra-Honigmann M.R., Nath A.K., Murakami C., Garcia-Cardena G., Papapetropoulos A., Sessa W.C., et al. Biological action of leptin as an angiogenic factor. Science 1998, 281:1683-1686.
146. Kaneko A., Satoh Y., Tokuda Y., Fujiyama C., Udo K., Uozumi J. Effects of adipocytes on the proliferation and differentiation of prostate cancer cells in a 3-D culture model. Int J Urol 2010, 17:369-376.
147. Meng L., Zhou J., Sasano H., Suzuki T., Zeitoun K.M., Bulun S.E. Tumor necrosis factor alpha and interleukin 11 secreted by malignant breast epithelial cells inhibit adipocyte differentiation by selectively down-regulating CCAAT/enhancer binding protein alpha and peroxisome proliferator-activated receptor gamma: mechanism of desmoplastic reaction. Cancer Res 2001, 61:2250-2255.